menu
    • menu

    Company profile for Ocugen

    NEW Drugs in Dev: 13
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for ocular Graft Versus Host Disease (oGVHD), if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases wi...
    Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for ocular Graft Versus Host Disease (oGVHD), if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OcugenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5 Great Valley Parkway, Suite 160 Malvern, PA 19355
    Telephone
    Telephone
    484.328.4701
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ocugen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ocugen
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Ocugen

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ocugen to Participate in June Investor and Industry Conferences
    Ocugen to Participate in June Investor and Industry Conferences

    02 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/02/3305012/0/en/ocugen-to-participate-in-upcoming-june-investor-and-industry-conferences.html

    GLOBENEWSWIRE
    02 Jun 2026
    Share Share
    Ocugen Closes $130M Convertible Senior Notes Offering
    Ocugen Closes $130M Convertible Senior Notes Offering

    14 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/14/3295430/0/en/ocugen-inc-announces-closing-for-130-0-million-of-6-75-convertible-senior-notes.html

    GLOBENEWSWIRE
    14 May 2026
    Share Share
    Ocugen Joins May Scientific & Investor Conferences
    Ocugen Joins May Scientific & Investor Conferences

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293857/0/en/ocugen-to-participate-in-upcoming-may-scientific-and-investor-conferences.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Ocugen Prices $115M Convertible Senior Notes Offering
    Ocugen Prices $115M Convertible Senior Notes Offering

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287656/0/en/ocugen-inc-announces-pricing-of-115-million-of-6-75-convertible-senior-notes.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Ocugen Updates Business With Q1 2026 Financial Results
    Ocugen Updates Business With Q1 2026 Financial Results

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287702/0/en/ocugen-provides-business-update-with-first-quarter-2026-financial-results.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Ocugen Launches $115M Convertible Senior Notes Offering
    Ocugen Launches $115M Convertible Senior Notes Offering

    04 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7268154

    FIRSTWORD PHARMA
    04 May 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search